Table 2.

Distribution of Serious Events^*

Serious Event Type	Serious Event Identified DURING ED Evaluation† n (%)	30-Day Serious Event Occurred AFTER ED Evaluation ╪ n (%)
Any	287 (10%)	173 (7%)
Death	0 (0%)	41 (1%)
Cardiac Event	198 (7%)	120 (4%)
Arrhythmia	175 (6%)	92 (3%)
Ventricular Tachycardia (VT)	25 (0.9%)	10 (0.4%)
VT Terminated by AICD	10 (0.3%)	0 (0%)
Sustained VT	5 (0.2%)	2 (0.1%)
Non-Sustained VT	10 (0.3%)	8 (0.3%)
Symptomatic PSVT	9 (0.3%)	6 (0.2%)
Symptomatic Atrial Fibrillation/Flutter with Rapid Ventricular Response	41 (1.4)%	18 (0.7%)
Sick Sinus Syndrome/Sinus Pause	23 (0.8%)	30 (1%)
Third or Mobitz II Heart Block	15 (0.5%)	9 (0.4%)
Symptomatic Bradycardia	76 (2.6%)	20 (0.8%)
Abnormal Electrophysiology Study	2 (0.1%)	5 (0.2%)
Myocardial Infarction	14 (0.5%)	6 (0.2%)
Cardiac Procedure	0 (0%)	54 (2%)
Pacemaker		40 (2%)
Implantable Defibrillator		7 (4%)
Coronary Angioplasty		3 (4%)
Coronary Bypass Surgery		4 (4%)
Structural Heart Disease	5 (0.2%)	10 (0.4%)
Pulmonary Embolism	7 (0.2%)	6 (0.3%)
Stroke/TIA	9 (0.3%)	11 (0.4%)
GI Bleed/Anemia	85 (3%)	8 (0.3%)
Subarachnoid Hemorrhage	1 (0.03%)	0 (0%)

^*Some patients experienced more than one event

^†These patients were excluded from further analysis;

Denominator includes 2,871 patients who met initial eligibility criteria

^╪Denominator includes 2,584 patients in the study cohort